Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.

Anat AchironMathilda MandelMichael GurevichSapir Dreyer-AlsterDavid MagalashviliPolina SonisMark DolevShay MenascuGil HarariShlomo FlechterRina Falb

Published in: Journal of neurology (2022)

Short period of fingolimod treatment discontinuation was associated with the development of humoral protection but not with adaptive cellular immunity.

Keyphrases

multiple sclerosis
immune response
white matter
coronavirus disease
sars cov
peripheral blood
dendritic cells
toll like receptor
combination therapy